Moolec Science SA Warrant (MLECW) Financials
Newest figures come from the 10-Q for Q2 FY2025, filed Apr 16, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MLECW SEC filings page.
Moolec Science SA Warrant (MLECW) reported $5.6M in revenue for fiscal year 2024, up 521.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but inventory-led working-capital absorption and external financing still define the operating model.
The net loss narrowed from-$51.8M in FY2023 to-$7.3M in FY2024, yet operating cash flow deteriorated, showing that accounting improvement did not translate into cash conversion. Inventory rose from$466K to$6.3M while receivables declined, indicating that more capital became tied up in stock rather than customer balances.
Revenue expanded from
Financing cash flow was
Financial Health Signals
Moolec Science SA Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Moolec Science SA Warrant passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Moolec Science SA Warrant reported a net loss of $7.3M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Moolec Science SA Warrant generated $2.6M in revenue in Q2 2025. This represents an increase of 948.3% from the same quarter a year earlier.
Moolec Science SA Warrant reported -$2.4M in net income in Q2 2025. This represents a decrease of 36.1% from the same quarter a year earlier.
Not reported for Q2 2025.
Not reported for Q2 2025.
Cash & Balance Sheet
Moolec Science SA Warrant held $1.9M in cash against $166K in long-term debt as of Q2 2025, with $6.5M of liabilities due within a year.
Not reported for Q2 2025.
Not reported for Q2 2025.
Margins & Returns
Moolec Science SA Warrant's net profit margin was -91.8% in Q2 2025, showing the share of revenue converted to profit. No change is given against Q2 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Moolec Science SA Warrant's ROE was -86.8% in Q2 2025, measuring profit generated per dollar of shareholder equity. This is down 60.1 percentage points from the same quarter a year earlier.
Not reported for Q2 2025.
Not reported for Q2 2025.
Capital Allocation
None of these metrics is reported for Q2 2025.
MLECW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M+948.3% | N/A | $252K | $1.7M | N/A | N/A | N/A | N/A |
| Interest Expense | $655K+611.4% | N/A | $92K | $93K+3099.6% | N/A | $86K+113.3% | N/A | -$3K |
| Income Tax | $281K+219.0% | N/A | -$236K | -$215K | N/A | N/A | N/A | N/A |
| Net Income | -$2.4M-36.1% | N/A | -$1.8M | -$1.6M-120.5% | N/A | N/A | N/A | -$721K |
| Diluted Shares (Avg) | 39M+3.1% | N/A | 38M | 38M+22.0% | N/A | 38M+21.2% | N/A | 31M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).
MLECW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.4M | $34.8M+44.6% | N/A | $22.5M | $24.1M+322.6% | $20.0M | $23.2M | N/A |
| Current Assets | $9.5M | $13.7M+157.9% | N/A | $3.2M | $5.3M+391.9% | $7.2M | $10.4M | N/A |
| Cash & Equivalents | $1.9M | $5.4M+113.2% | N/A | $854K | $2.5M+133.7% | $6.2M+421.9% | $10.4M | N/A |
| Inventory | $4.8M+865.9% | $6.3M+1248.3% | $502K | $390K | $466K | N/A | N/A | N/A |
| Accounts Receivable | $809K | $1.0M-24.0% | N/A | N/A | $1.3M | N/A | N/A | N/A |
| Goodwill | $281K | $263K+4.4% | N/A | $248K | $251K-94.5% | $4.7M | N/A | N/A |
| Total Liabilities | $28.6M | $28.0M+100.6% | N/A | $13.6M | $13.9M+241.2% | $8.4M | $11.3M | N/A |
| Current Liabilities | $6.5M | $8.2M-35.3% | N/A | $12.5M | $12.6M+208.2% | $8.4M | $11.3M | N/A |
| Non-Current Liabilities | $22.1M | $19.8M+1372.4% | N/A | $1.1M | $1.3M | $0 | $0 | N/A |
| Long-Term Debt | $166K | $249K | N/A | $244K | N/A | $2K | $1K | N/A |
| Total Equity | $2.8M-58.2% | $6.8M-32.6% | $6.7M-43.8% | $8.9M+907.1% | $10.1M+529.9% | $11.6M+278.9% | $11.9M | $883K |
| Retained Earnings | -$70.3M | -$65.9M-12.5% | N/A | -$60.2M | -$58.6M-757.8% | -$55.9M | -$55.5M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
MLECW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$3.9M-558.8% | -$1.7M-18171.8% | -$2.7M-337.6% | -$4.3M-870.6% | -$593K | $10K |
| Depreciation & Amortization | N/A | N/A | N/A | $181K+42399.5% | $121K+28311.3% | $4250.0% | $424 | $425 |
| Capital Expenditures | N/A | N/A | -$8K | $104K | $12K | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$3.9M | -$1.8M | -$2.7M | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$2.2M | -$82K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $4.8M | -$127K | $1.3M+156.3% | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.
MLECW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Net Margin | -91.8% | N/A | -707.4% | -91.4% | N/A | N/A | N/A | N/A |
| Return on Equity | -86.8%-60.1pp | N/A | -26.7% | -17.9%+63.8pp | N/A | N/A | N/A | -81.7% |
| Return on Assets | -7.7% | N/A | N/A | -7.1% | N/A | N/A | N/A | N/A |
| Current Ratio | 1.48 | 1.69+1.3x | N/A | 0.26 | 0.42+0.2x | 0.85 | 0.93 | N/A |
| Debt-to-Equity | 0.06 | 0.04-1.3x | N/A | 0.03 | 1.38+1.4x | 0.00 | 0.00 | N/A |
| Asset Turnover | 0.08 | N/A | N/A | 0.08 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | -1551.6% | -106.2% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Moolec Science SA Warrant MLECW | FY2024 | $5.6M | -$7.3M | N/A | N/A | — |
| Aspire-Lakewood Holdings, Inc. Warrant ASBPW | FY2025 | $6K | N/A | N/A | N/A | — |
| BriaCell Therapeutics Corp. Warrant BCTXW | FY2025 | N/A | -$26.3M | N/A | N/A | — |
| BriaCell Therapeutics Corp. Warrant BCTXZ | FY2025 | N/A | -$26.3M | N/A | N/A | — |
Where Moolec Science SA Warrant Ranks
Frequently Asked Questions
What is Moolec Science SA Warrant's annual revenue?
Moolec Science SA Warrant (MLECW) reported $5.6M in total revenue for fiscal year 2024. This represents a 521.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Moolec Science SA Warrant's revenue growing?
Moolec Science SA Warrant (MLECW) revenue grew by 521.5% year-over-year, from $905K to $5.6M in fiscal year 2024.
Is Moolec Science SA Warrant profitable?
No, Moolec Science SA Warrant (MLECW) reported a net income of -$7.3M in fiscal year 2024.
How much debt does Moolec Science SA Warrant have?
As of fiscal year 2024, Moolec Science SA Warrant (MLECW) had $5.4M in cash and equivalents against $249K in long-term debt.
What is Moolec Science SA Warrant's return on equity (ROE)?
Moolec Science SA Warrant (MLECW) has a return on equity of -107.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Moolec Science SA Warrant's free cash flow?
Moolec Science SA Warrant (MLECW) recorded an outflow of $9.5M in free cash flow during fiscal year 2024. This represents a -26.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Moolec Science SA Warrant's operating cash flow?
Moolec Science SA Warrant (MLECW) recorded an outflow of $9.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Moolec Science SA Warrant's total assets?
Moolec Science SA Warrant (MLECW) had $34.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Moolec Science SA Warrant's capital expenditures?
Moolec Science SA Warrant (MLECW) invested $158K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Moolec Science SA Warrant's current ratio?
Moolec Science SA Warrant (MLECW) had a current ratio of 1.69 as of fiscal year 2024, which is generally considered healthy.
What is Moolec Science SA Warrant's debt-to-equity ratio?
Moolec Science SA Warrant (MLECW) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Moolec Science SA Warrant's return on assets (ROA)?
Moolec Science SA Warrant (MLECW) had a return on assets of -21.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Moolec Science SA Warrant's Piotroski F-Score?
Moolec Science SA Warrant (MLECW) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Moolec Science SA Warrant's earnings high quality?
Moolec Science SA Warrant (MLECW) reported a net loss of $7.3M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.